Delayed immune-mediated side effects after Nivolumab-therapy in an HNSCC-patient

被引：0
|
作者：
Burmeister, A. -S. [1 ]
Stubbe, F. [1 ]
Langenkamp, U. [1 ]
Junghanss, C. [1 ]
Grosse-Thie, C. [1 ]
机构：
[1] Rostock Univ Med Ctr, Dept Med, Clin Hematol 3, Oncol,Palliat Med, Rostock, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
565
引用
收藏
页码：134 / 134
页数：1
相关论文
共 50 条
  • [21] Immune-Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis
    Bolte, Fabian J.
    Schmidt, Hartmut H. -J.
    Schlevogt, Bernhard
    HEPATOLOGY, 2021, 73 (01) : 460 - 463
  • [22] TNF-α-Blockade in Melanoma as a Prophylaxis of immune-mediated Side Effects after Re-exposure to Immune Checkpoint Inhibitors
    Koch, F.
    Olischewsky, A.
    Lodde, G.
    Aschoewer, J.
    Schneider, M.
    Roesch, A.
    Ugurel, S.
    Schadendorf, D.
    Livingstone, E.
    Zimmer, L.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 43 - 44
  • [23] Cutaneous side-effects of biologics in immune-mediated disorders: A histopathological perspective
    Succaria, Farah
    Bhawan, Jag
    JOURNAL OF DERMATOLOGY, 2017, 44 (03): : 243 - 250
  • [24] IMMUNE-MEDIATED HEMOLYTIC-DISEASE AFTER PENICILLIN THERAPY IN A HORSE
    ROBBINS, RL
    WALLACE, SS
    BRUNNER, CJ
    GARDNER, TR
    DIFRANCO, BJ
    SPEIRS, VC
    EQUINE VETERINARY JOURNAL, 1993, 25 (05) : 462 - 465
  • [25] Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma
    Kang, S.
    Lee, H. J.
    Lee, H. J.
    JOURNAL OF POSTGRADUATE MEDICINE, 2023, 69 (03) : 172 - +
  • [26] Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient
    Abhyankar, Anita
    Tapper, Elliot B.
    Bonder, Alan
    PHARMACEUTICALS, 2014, 7 (01): : 18 - 28
  • [27] Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review
    Fu, Shengya
    Wang, Ting
    Xu, Feng
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (06) : 1548 - 1552
  • [28] Basiliximab therapy for immune-mediated bowel disease in a pediatric heart transplant patient
    Kiskaddon, Amy L.
    Wilsey, Michael
    Gonzalez-Gomez, Ignacio
    Laks, Jessica
    Miles, Alyssa
    Carapellucci, Jennifer
    Asante-Korang, Alfred
    PEDIATRIC TRANSPLANTATION, 2023, 27 (02)
  • [29] Liver injury induced by immune checkpoint inhibitor-therapy. Example of an immune-mediated drug side effect
    Straub, B. K.
    Ridder, D. A.
    Schad, A.
    Loquai, C.
    Schattenberg, J. M.
    PATHOLOGE, 2018, 39 (06): : 556 - 562
  • [30] Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis
    Li, Michael
    Sack, Jordan S.
    Rahma, Osama E.
    Hodi, F. Stephen
    Zucker, Stephen D.
    Grover, Shilpa
    CANCER, 2020, 126 (23) : 5088 - 5097
12345